B.R.A.I.N. Biotechnology Research and Information Network (BNN) AI Stock Analysis

• Market Cap: €47.85M
• Dividend Yield: N/A
• Average Volume (3M): 4.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.53
• Revenue Growth: -4.90%
• EPS Growth: -69.80%
• Country: DE
• Employees: 296
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 21,847,494
• 10 Day Avg. Volume: 6,637
• 30 Day Avg. Volume: 4,531
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €2.00
• Price Target Upside: -13.04% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: €2.00 ▼(-13.04% Downside)

B.R.A.I.N. Biotechnology Research and Information Network's stock score is primarily impacted by its financial performance, which shows significant challenges in profitability and liquidity. Technical analysis suggests a neutral trend with potential for upward movement, but valuation remains a concern due to negative earnings and lack of dividends. The absence of earnings call data and corporate events limits additional insights.

B.R.A.I.N. Biotechnology Research and Information Network Business Overview & Revenue Model

Company Description

BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.

How the Company Makes Money

BNN generates revenue through multiple streams, including consultancy fees for research services provided to academic institutions and corporate clients, subscription fees for access to its proprietary databases and research findings, and licensing agreements for its patented technologies and products. Additionally, BNN collaborates with pharmaceutical companies and agricultural firms in joint research projects, which often include funding and investment from these partners. Strategic partnerships with universities and research institutions also contribute to funding through grants and collaborative projects, enhancing BNN's financial stability and growth potential.

B.R.A.I.N. Biotechnology Research and Information Network Financial Statement Overview

Summary

B.R.A.I.N. Biotechnology Research and Information Network faces financial challenges, with persistent net losses and negative cash flows. While revenue growth indicates potential, profitability and liquidity remain concerns. The balance sheet shows improvement in debt management, but overall financial stability is a challenge.

Income Statement

The company shows a concerning trajectory with consistent net losses and declining profit margins. The TTM data indicates a negative EBIT and EBITDA, suggesting operational inefficiencies. Revenue has shown some growth over the years, but the net profit margin remains negative, indicating profitability challenges.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio, but recent TTM data suggests no total debt, indicating improvement in leverage. The equity ratio is low, reflecting potential risk. Historical stockholders' equity decline suggests financial instability.

Cash Flow

Operating cash flow is negative, indicating difficulties in generating cash from operations. Free cash flow remains negative, though recent financing activities have improved liquidity. The consistent negative free cash flow to net income ratio highlights ongoing cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	54.63M	55.34M	49.51M	38.39M	38.23M
Gross Profit	30.33M	3.47M	27.45M	21.57M	21.20M
EBITDA	-4.23M	-1.98M	-1.30M	2.01M	-2.78M
Net Income	-11.13M	-8.28M	-6.59M	-4.97M	-9.68M
Balance Sheet
Total Assets	88.74M	70.94M	77.99M	77.74M	72.15M
Cash, Cash Equivalents and Short-Term Investments	27.29M	5.41M	8.53M	24.65M	19.05M
Total Debt	12.80M	4.66M	3.04M	2.64M	30.60M
Total Liabilities	74.85M	47.92M	43.74M	35.91M	46.01M
Stockholders Equity	12.62M	21.77M	29.64M	38.78M	20.79M
Cash Flow
Free Cash Flow	-5.31M	-6.86M	-7.57M	-5.17M	-7.63M
Operating Cash Flow	-3.58M	-4.22M	-1.49M	-3.91M	-4.77M
Investing Cash Flow	-1.69M	562.00K	-12.69M	-2.18M	-4.47M
Financing Cash Flow	26.99M	459.00K	-1.97M	11.57M	13.09M

B.R.A.I.N. Biotechnology Research and Information Network Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BNN, the sentiment is Positive. The current price of 2.3 is above the 20-day moving average (MA) of 2.12, above the 50-day MA of 2.08, and below the 200-day MA of 2.55, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 59.27 is Neutral, neither overbought nor oversold. The STOCH value of 50.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:BNN.

B.R.A.I.N. Biotechnology Research and Information Network Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
BNN	47 Neutral	€47.85M	―	-111.86%	―	-4.90%	-69.80%
0R6U	―	€5.58M	―	-288.87%	―	―	―
0DOL	―	€15.50M	541.55	-22.41%	―	―	―
0EL9	―	€16.88M	9.97	8.35%	―	―	―
0QW5	―	€159.92M	―	-78.11%	―	―	―
T5O0	―	€419.31K	―		―	―	―